Category: MedCity News

Healthcare and Gen X: 4 Things Marketers Need to Get Right

Healthcare and Gen X: 4 Things Marketers Need to Get Right

MedCity News

When it comes to healthcare marketing, Generation X once again gets the short end of the attention stick.
Overshadowed by boomers—a prime target for healthcare advertising dollars as they age and require more care—and Millennials—the holy grail audience for the emerging health-tech industry—Gen X’s unique healthcare needs and position often leave its members underserved and mostly ignored. This oversight is a massive missed opportunity for healthcare marketers. First off, Gen X is at the height of its spending potential. Its U.S. population of 65 million has saved a collective $13 trillion and owns 29% of the nation’s household wealth (versus just 6.4%…

Continue Reading
Which Moves Should Providers Watch From Amazon, CVS & Walgreens This Year?

Which Moves Should Providers Watch From Amazon, CVS & Walgreens This Year?

MedCity News

Primary care has been historically dominated by traditional providers that deliver care via fee-for-service models, but retail companies have been amping up their efforts to disrupt the space in recent years. Over the next decade, it will become increasingly difficult for hospitals and other traditional healthcare providers to ignore these disruptors, according to a recent report from the American Hospital Association. 
The report cited a Bain & Company analysis that predicted disruptors could own as much as 30% of the $260 billion primary care market by 2030. So what moves by Amazon, Walmart and CVS will the industry need to watch to…

Continue Reading
Few Managed Care Plans Have Current Contact Info for Medicaid Members as Redeterminations Loom

Few Managed Care Plans Have Current Contact Info for Medicaid Members as Redeterminations Loom

MedCity News

Just about one-third of managed care plans have verified or current contact information for between 76% and 100% of their Medicaid members, a recent survey found. 
The news comes as the Medicaid continuous enrollment provision is set to expire March 31 due to the Consolidated Appropriations Act. The requirement was part of the Families First Coronavirus Response Act and banned states from disenrolling people from Medicaid during the public health emergency (although the Consolidated Appropriations Act separated the requirement from the PHE, which will end in May). Starting April 1, states can resume disenrollments and Medicaid enrollees will have to undergo the…

Continue Reading
We’re Feeling the Effects of the Nursing Shortage. Technology Can Help.

We’re Feeling the Effects of the Nursing Shortage. Technology Can Help.

MedCity News

The healthcare industry is in desperate need of nurses — and fast. Chances are this isn’t news to you. You’ve seen the countless headlines covering the impact the pandemic has had on nurses, and how that nursing shortage has impacted employment numbers, healthcare facilities, and patient care.
Nurses are burnt out. They’re stressed, exhausted, and struggling to find adequate mental health support. But the pandemic isn’t the only issue to blame. Experts are predicting that over 1 million RNs will likely retire by 2030, which will only add to the heaviness of the nursing shortage. An overly-stressed out and aging workforce of…

Continue Reading
Where Are All the Patients?

Where Are All the Patients?

MedCity News

It’s no secret that patient enrollment is one of clinical research’s biggest hurdles. According to an analysis of trials listed, 55% of terminated trials were ended because of low patient enrollment. The analysis also reported that Phase III and Phase IV trials have an enrollment efficiency of less than 40%. Yet another analysis found more than 80% of studies do not enroll on time, often leading to a study extension or additional research sites.
The problem isn’t just enrollment, it’s also the enrollment of diverse patients. Racial and ethnic minorities, specifically Black or African American, Hispanic/Latino, Indigenous and Native American, Asian, Native…

Continue Reading
Rising Costs Are Keeping Healthcare CFOs Up a Night — Can Data Help?

Rising Costs Are Keeping Healthcare CFOs Up a Night — Can Data Help?

MedCity News

The increasing costs of labor and supplies are the top issues keeping healthcare CFOs up at night, according to a new report released by Syntellis, a provider of performance management software. To effectively address these concerns, healthcare providers must ensure they have access to data-driven analytics software that can help them make important decisions — such as how to effectively manage their existing workforce and where to shift care delivery models — the report said.
Syntellis surveyed more than 200 U.S. healthcare finance professionals who work at hospitals, health systems and integrated delivery networks. These professionals agreed that last year was a…

Continue Reading
Caraway, Ash Wellness Launch Partnership to Combat Rise in STIs on College Campuses

Caraway, Ash Wellness Launch Partnership to Combat Rise in STIs on College Campuses

MedCity News

In order to catch the attention of reporters, companies often look for creative news hooks to tie their announcements to. Two companies have decided to use Valentine’s Day to forward their message of sexually transmitted infection prevention. How romantic!
Digital health startup Caraway Health is teaming up with at-home testing company Ash Wellness to provide STI kits for those aged 18 to 27, the companies announced Tuesday. New York City-based Caraway provides mental, physical and reproductive health services for Gen-Z populations, with a particular focus on women and people assigned female at birth. It offers an app that enables users to access its…

Continue Reading
GSK’s Covid-19 Valentine to Vir Biotech: ‘You Can Go Your Own Way’

GSK’s Covid-19 Valentine to Vir Biotech: ‘You Can Go Your Own Way’

MedCity News

Vir Biotechnology’s Covid-19 research may yield more drugs and perhaps a vaccine, but no longer with the financial support of GSK. The collaboration agreement the two companies struck up in the early days of the pandemic has been amended, leaving Vir to either find another partner or continue its coronavirus research on its own.
The alliance did successfully develop the Covid-19 drug sotrovimab. GSK and Vir will continue to share responsibilities for that drug, which is available under the brand name Xevudy in more than 40 countries. The U.S. is no longer one of them. Last April, the FDA withdrew emergency authorization…

Continue Reading
Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

Adverse Survival Signal Leads G1 to Stop Pivotal Test in Colorectal Cancer

MedCity News

G1 Therapeutics’ approach to cancer does not kill tumors. Instead, the biotech’s drug, trilaciclib, protects bone marrow from the damaging effects of chemotherapy, reducing the duration and severity of the problems that can limit the use of this cancer treatment. Since trilaciclib’s initial approval insmall cell lung cancer, G1 has pursued more clinical trials that could support expanding the drug to other cancers. Colorectal cancer will no longer be one of them.
On Monday, G1 reported preliminary data showing that the placebo group outperformed the trilaciclib arm in helping patients live longer. G1 said it has decided to stop the colorectal cancer…

Continue Reading